Cargando…

Serum PCSK9 levels, but not PCSK9 polymorphisms, are associated with CAD risk and lipid profiles in southern Chinese Han population

BACKGROUND: Genetic and environment factors affect the occurrence and development of coronary artery disease (CAD). Proprotein convertase subtilisin/kexin type 9 (PCSK9), has been investigated extensively in the field of lipid metabolism and CAD. We performed this case-control study to investigate t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cai, Gaojun, Yu, Lei, Huang, Zhiying, Li, Li, Fu, Xingli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134597/ https://www.ncbi.nlm.nih.gov/pubmed/30205809 http://dx.doi.org/10.1186/s12944-018-0859-5

Ejemplares similares

Polymorphisms in PCSK9, LDLR, BCMO1, SLC12A3, and KCNJ1 Are Associated with Serum Lipid Profile in Chinese Han Population
por: Li, Zheng, et al.
Publicado: (2019)

PCSK9 and Atherosclerosis - Lipids and Beyond
por: Shapiro, Michael D., et al.
Publicado: (2017)

Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations
por: Mayne, Janice, et al.
Publicado: (2013)

Correlation of PCSK9 Gene Polymorphism with Cerebral Ischemic Stroke in Xinjiang Han and Uygur Populations
por: Han, Dengfeng, et al.
Publicado: (2014)

PCSK9 targets important for lipid metabolism
por: Schulz, Rainer, et al.
Publicado: (2017)

The association of the PCSK9 rs562556 polymorphism with serum lipids level: a meta-analysis
por: Chuan, Junlan, et al.
Publicado: (2019)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

Association between the DOCK7, PCSK9 and GALNT2 Gene Polymorphisms and Serum Lipid levels
por: Guo, Tao, et al.
Publicado: (2016)

Lipid Lowering Therapy and Circulating PCSK9 Concentration
por: Nozue, Tsuyoshi
Publicado: (2017)

The Multifaceted Biology of PCSK9
por: Seidah, Nabil G, et al.
Publicado: (2021)

Autocrine effects of PCSK9 on cardiomyocytes
por: Wolf, Annemarie, et al.
Publicado: (2020)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
por: Ko, Dennis T., et al.
Publicado: (2018)

The effect of PCSK9 immunization on the hepatic level of microRNAs associated with the PCSK9/LDLR pathway
por: Ataei, Sarina, et al.
Publicado: (2023)

Susceptibility of PCSK2 Polymorphism to Hirschsprung Disease in Southern Chinese Children
por: Wang, Bingtong, et al.
Publicado: (2023)

E670G PCSK9 polymorphism in HeFH & CAD with diabetes: is the bridge to personalized therapy within reach?
por: Alieva, Rano, et al.
Publicado: (2023)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2014)

An Update on the Role of PCSK9 in Atherosclerosis
por: Yurtseven, Ece, et al.
Publicado: (2020)

Naturally Occurring PCSK9 Inhibitors
por: Adorni, Maria Pia, et al.
Publicado: (2020)

PCSK9 Monoclonal Antibodies: An Overview
por: Kaddoura, Rasha, et al.
Publicado: (2020)

Pleiotropic Effects of PCSK-9 Inhibitors
por: Basiak, Marcin, et al.
Publicado: (2021)

Phage display for targeting PCSK9
por: Ferri, Nicola
Publicado: (2021)

Insight into the Evolving Role of PCSK9
por: Maligłówka, Mateusz, et al.
Publicado: (2022)

Gene Therapy Targeting PCSK9
por: Katzmann, Julius L., et al.
Publicado: (2022)

PCSK9 as an Atherothrombotic Risk Factor
por: Sotler, Tadeja, et al.
Publicado: (2023)

Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors
por: Levstek, Tina, et al.
Publicado: (2023)

Circulating PCSK9 levels and 2-hPG are positively correlated in metabolic diseases in a Chinese Han population
por: Guo, Wen, et al.
Publicado: (2018)

Association of genetic polymorphisms of PCSK9 with type 2 diabetes in Uygur Chinese population
por: Wang, Meng-Meng, et al.
Publicado: (2022)

Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly
por: Holla, Øystein L, et al.
Publicado: (2007)

Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts
por: Nguyen, My-Anh, et al.
Publicado: (2014)

The R93C Variant of PCSK9 Reduces the Risk of Premature MI in a Chinese Han Population
por: Yang, Lincheng, et al.
Publicado: (2022)

The association between circulatory, local pancreatic PCSK9 and type 2 diabetes mellitus: The effects of antidiabetic drugs on PCSK9
por: Lu, Fengyuan, et al.
Publicado: (2023)

Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain
por: Poirier, Steve, et al.
Publicado: (2016)

PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells
por: Zulkapli, Rahayu, et al.
Publicado: (2023)

PCSK9 inhibitors: A new era of lipid lowering therapy
por: Chaudhary, Rahul, et al.
Publicado: (2017)

PCSK9 and Calcific Aortic Valve Stenosis: Moving Beyond Lipids
por: Leopold, Jane A.
Publicado: (2020)

PCSK9 in Myocardial Infarction and Cardioprotection: Importance of Lipid Metabolism and Inflammation
por: Andreadou, Ioanna, et al.
Publicado: (2020)

Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall
por: Ugovšek, Sabina, et al.
Publicado: (2022)

PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity
por: Alannan, Malak, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cejsi3ssd1d3s6bniq4m9c5ull